Australian IntraCranial Haemorrhage Registry - a registry study to assess the clinical management and adherence to national treatment guidelines for adults who have experienced bleeding in the brain.

Australian IntraCranial Hemorrhage Registry - A study to assess current management, adherence to national guidelines and patient outcomes in adults who have suffered an intracranial hemorrhage, including spontaneous non-traumatic intracerebral hemorrhage, non-penetrative traumatic hemorrhage, and anticoagulant-associated intracranial hemorrhage.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12624000072516

Acronym

AustrICH

Enrollment

Registered

2024-01-29

Start date

2023-12-13

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To assess current management, including adherence to national guidelines, and outcomes in patients with intracranial haemorrhage. To also improve adherence to guidelines through the use of an integrated continuous Quality Improvement program assessing key performance indicators of blood pressure control and reversal of anticoagulant medications.

Interventions

The exposure of interest are adult patients with intracranial hemorrhage. We will assess current management, including adherence to national guidelines, and outcomes in patients with intracranial hemorrhage. Data is collected within the first 24 hours of hospital presentation, day 7 and day 30, including vital signs, medications, neurological assessments and radiological imaging. Patient outcomes will be monitored biannually over 5 years via phone call. They will be asked questions about daily

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age 18 years or older 2. Radiographically confirmed intracranial hemorrhage (intracerebral, intraventricular, subarachnoid or subdural) either spontaneous or secondary 3. If SDH or SAH, patients must also be currently treated with an OAC (VKA, rivaroxaban, apixaban, dabigatran). 4. Time from symptom onset (or last known well) less than 24 hours prior to the baseline imaging scan.

Exclusion criteria

1. Penetrating intracranial injury (other traumatic intracranial haemorrhage is eligible). 2. Haemorrhagic transformation of an ischaemic infarct. 3. Haemorrhage secondary to cerebral venous sinus thrombosis.

Outcome results